Contact CFFC

Jan

Clinical Trial Alerts – January 2021

Cystic Fibrosis Foundation issued the following clinical trial alerts on January 4, 2021. Note, although two of the trials have the same title, they apply to different age groups.

Phase 2 study of JBT-101 in people with CF

Status: Completed with results

Description: This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.

Age: 18 Years to 65 Years

Mutation: No Mutation Requirement

Fev1% Predicted: 40% or greater

Number of Visits: 8

Length of Participation: 127 days

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02465450

Phase 2 study of JBT-101 in people with CF

Status: Completed with results

Description: This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.

Age: 12 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40 to 100%

Number of Visits: 10

Length of Participation: 32 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03451045

TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF

Status: Completed with results

Description: This study evaluated the effect of adding oral azithromycin to inhaled tobramycin in people with CF who are chronically infected with P. aeruginosa.

Age: 12 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 25 to 100%

Number of Visits: 5

Length of Participation: 14 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02677701


Comments are closed.